<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35435637</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">2193-8210</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>12</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
            </PubDate>
          </JournalIssue>
          <Title>Dermatology and therapy</Title>
          <ISOAbbreviation>Dermatol Ther (Heidelb)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysis.</ArticleTitle>
        <Pagination>
          <StartPage>1181</StartPage>
          <EndPage>1196</EndPage>
          <MedlinePgn>1181-1196</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s13555-022-00721-1</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The comparative efficacy of targeted systemic therapies for moderate to severe atopic dermatitis (AD) has not been systematically assessed using recent phase 3 data. This network meta-analysis assesses the comparative efficacy of targeted systemic therapies without the addition of topical corticosteroids (TCS) and/or topical calcineurin inhibitors (TCI) in adults with moderate to severe AD.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">The systematic literature review searched through 17 May 2021 for phase 3/4 trials with upadacitinib, interleukin-4 (IL-4), interleukin-13 (IL-13), or JAK inhibitors compared with placebo or active intervention for adults and adolescents with moderate to severe AD with inadequate response to TCS/TCI or for whom TCS/TCI was medically inadvisable, without restrictions on year or region. Researchers assessed data using PRISMA guidelines. The proportion of patients achieving trial co-primary endpoints [Investigator Global Assessment (IGA) score of 0 or 1 (clear or almost clear) and reduction of ≥ 2 points from baseline; proportion of patients achieving Eczema Area and Severity Index (EASI) improvement ≥ 75% from baseline (EASI-75)]; EASI improvement ≥ 90% from baseline (EASI-90); and ≥ 4-point improvement on Pruritus Numerical Rating Scale from baseline (ΔNRS ≥ 4) were evaluated using Bayesian network meta-analysis.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 3415 initially identified records, network meta-analysis (NMA) ultimately included 6 records representing 9 unique studies. Two upadacitinib trials were also included. Eleven clinical trials including 6254 patients were analyzed. Upadacitinib 30 mg daily was the most efficacious therapy across all endpoints at the primary endpoint (week 12 or 16) and at earlier timepoints, followed by upadacitinib 15 mg daily and abrocitinib 200 mg daily.</AbstractText>
          <AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Many factors need to be considered for treatment selection for AD. These findings can help healthcare providers when personalizing a patient's treatment.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Upadacitinib 30 mg daily, upadacitinib 15 mg daily, and abrocitinib 200 mg daily may be the most efficacious targeted systemic therapies over 12-16 weeks of therapy in AD.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Silverberg</LastName>
            <ForeName>Jonathan I</ForeName>
            <Initials>JI</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, The George Washington University School of Medicine and Health Sciences, 2150 Pennsylvania Ave NW, Ste 2B-425, Washington, DC, 20037, USA. jonathanisilverberg@gmail.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hong</LastName>
            <ForeName>H Chih-Ho</ForeName>
            <Initials>HC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Probity Medical Research, Surrey, BC, Canada.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thyssen</LastName>
            <ForeName>Jacob P</ForeName>
            <Initials>JP</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Calimlim</LastName>
            <ForeName>Brian M</ForeName>
            <Initials>BM</Initials>
            <AffiliationInfo>
              <Affiliation>AbbVie Inc, North Chicago, IL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Joshi</LastName>
            <ForeName>Avani</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>AbbVie Inc, North Chicago, IL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Teixeira</LastName>
            <ForeName>Henrique D</ForeName>
            <Initials>HD</Initials>
            <AffiliationInfo>
              <Affiliation>AbbVie Inc, North Chicago, IL, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Collins</LastName>
            <ForeName>Eric B</ForeName>
            <Initials>EB</Initials>
            <AffiliationInfo>
              <Affiliation>Medicus Economics LLC, Boston, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Crowell</LastName>
            <ForeName>Marjorie M</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>Medicus Economics LLC, Boston, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Johnson</LastName>
            <ForeName>Scott J</ForeName>
            <Initials>SJ</Initials>
            <AffiliationInfo>
              <Affiliation>Medicus Economics LLC, Boston, MA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Armstrong</LastName>
            <ForeName>April W</ForeName>
            <Initials>AW</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Dermatol Ther (Heidelb)</MedlineTA>
        <NlmUniqueID>101590450</NlmUniqueID>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Atopic dermatitis</Keyword>
        <Keyword MajorTopicYN="N">EASI</Keyword>
        <Keyword MajorTopicYN="N">IGA</Keyword>
        <Keyword MajorTopicYN="N">Network meta-analysis</Keyword>
        <Keyword MajorTopicYN="N">Pruritus NRS</Keyword>
        <Keyword MajorTopicYN="N">Systematic literature review</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>18</Day>
          <Hour>12</Hour>
          <Minute>10</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35435637</ArticleId>
        <ArticleId IdType="pmc">PMC9110624</ArticleId>
        <ArticleId IdType="doi">10.1007/s13555-022-00721-1</ArticleId>
        <ArticleId IdType="pii">10.1007/s13555-022-00721-1</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Sánchez-Pérez J, Daudén-Tello E, Mora AM, et al.  Impact of atopic dermatitis on health-related quality of life in Spanish children and adults: the PSEDA study. Actas Dermosifiliogr. 2013;104(1):44–52. doi: 10.1016/j.ad.2012.03.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ad.2012.03.008</ArticleId>
            <ArticleId IdType="pubmed">22841507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silverberg JI, Garg NK, Paller AS, et al.  Sleep disturbances in adults with eczema are associated with impaired overall health: a US population-based study. J Invest Derm. 2015;135(1):56–66. doi: 10.1038/jid.2014.325.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/jid.2014.325</ArticleId>
            <ArticleId IdType="pubmed">25078665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simpson EL, Bieber T, Eckert L, et al.  Patient burden of moderate to severe atopic dermatitis (AD): insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016;74(3):491–498. doi: 10.1016/j.jaad.2015.10.043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaad.2015.10.043</ArticleId>
            <ArticleId IdType="pubmed">26777100</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drucker AM, Wang AR, Qureshi AA. Research gaps in quality of life and economic burden of atopic dermatitis: the National Eczema Association Burden of Disease Audit. JAMA Dermatol. 2016;152(8):873–874. doi: 10.1001/jamadermatol.2016.1978.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamadermatol.2016.1978</ArticleId>
            <ArticleId IdType="pubmed">27305113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sibbald C, Drucker AM. Patient burden of atopic dermatitis. Dermatol Clin. 2017;35(3):303–316. doi: 10.1016/j.det.2017.02.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.det.2017.02.004</ArticleId>
            <ArticleId IdType="pubmed">28577800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Von Kobyletzki LB, Thomas KS, Schmitt J, et al.  What factors are important to patients when assessing treatment response: an international crosssectional survey. Acta Derm Venereol. 2017;97(1):86–90. doi: 10.2340/00015555-2480.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2340/00015555-2480</ArticleId>
            <ArticleId IdType="pubmed">27305646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eichenfield LF, Tom WL, Berger TG, et al.  Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132. doi: 10.1016/j.jaad.2014.03.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaad.2014.03.023</ArticleId>
            <ArticleId IdType="pmc">PMC4326095</ArticleId>
            <ArticleId IdType="pubmed">24813302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McCollum AD, Paik A, Eichenfield LF. The safety and efficacy of tacrolimus ointment in pediatric patients with atopic dermatitis. Pediatr Dermatol. 2010;27(5):425–436. doi: 10.1111/j.1525-1470.2010.01223.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1525-1470.2010.01223.x</ArticleId>
            <ArticleId IdType="pubmed">20678096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johansson SG, Bieber T, Dahl R, et al.  Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113(5):832–836. doi: 10.1016/j.jaci.2003.12.591.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2003.12.591</ArticleId>
            <ArticleId IdType="pubmed">15131563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Odhiambo JA, Williams HC, Clayton TO, et al.  Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol. 2009;124(6):1251–1258. doi: 10.1016/j.jaci.2009.10.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaci.2009.10.009</ArticleId>
            <ArticleId IdType="pubmed">20004783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). January 2021. Identifier NCT03738397. A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis (Heads Up). Available from: https://clinicaltrials.gov/ct2/show/NCT03738397?term=NCT03738397&amp;draw=2&amp;rank=1</Citation>
        </Reference>
        <Reference>
          <Citation>Catalá-López F, Tobías A, Cameron C, et al.  Network meta-analysis for comparing treatment effects of multiple interventions: an introduction. Rheumatol Int. 2014;34(11):1489–1496. doi: 10.1007/s00296-014-2994-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00296-014-2994-2</ArticleId>
            <ArticleId IdType="pubmed">24691560</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Higgins JPT, Thomas J, Chandler J et al. (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane; 2019. http://www.training.cochrane.org/handbook.</Citation>
        </Reference>
        <Reference>
          <Citation>National Institute for Health and Care Excellence (NICE). Guide to the methods of technology appraisal. Process and methods [PMG9]. https://www.nice.org.uk/process/pmg9/chapter/foreword#. Published 2013.</Citation>
        </Reference>
        <Reference>
          <Citation>Centre for Reviews and Dissemination (CRD)   Systematic reviews: guidance for undertaking reviews in health care. York: CRD, University of York; 2009. </Citation>
        </Reference>
        <Reference>
          <Citation>Guttman-Yassky E, Teixeira HD, Simpson EL, et al.  Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151–2168. doi: 10.1016/S0140-6736(21)00588-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(21)00588-2</ArticleId>
            <ArticleId IdType="pubmed">34023008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simpson E, Bissonnette R, Eichenfield LF, et al.  The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): the development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J Am Acad Dermatol. 2020;83(3):839–846. doi: 10.1016/j.jaad.2020.04.104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaad.2020.04.104</ArticleId>
            <ArticleId IdType="pubmed">32344071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leshem YA, Hajar T, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172(5):1353–1357. doi: 10.1111/bjd.13662.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjd.13662</ArticleId>
            <ArticleId IdType="pubmed">25580670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yosipovitch G, Reaney M, Mastery V, et al.  Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. Br J Dermatol. 2019;181(4):761–769. doi: 10.1111/bjd.17744.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjd.17744</ArticleId>
            <ArticleId IdType="pmc">PMC6850643</ArticleId>
            <ArticleId IdType="pubmed">30729499</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bormann, DigitizeIt (version 2.5), 2001–2020. http://www.digitizeit.de/</Citation>
        </Reference>
        <Reference>
          <Citation>Cope S, Zhang J, Saletan S, et al.  A process for assessing the feasibility of a network meta-analysis: a case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Med. 2014;12(1):93. doi: 10.1186/1741-7015-12-93.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1741-7015-12-93</ArticleId>
            <ArticleId IdType="pmc">PMC4077675</ArticleId>
            <ArticleId IdType="pubmed">24898705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chou JS, LeBovidge J, Timmons K, et al.  Predictors of clinical success in a multidisciplinary model of atopic dermatitis treatment. Allergy Asthma Proc. 2011;32(5):377–383. doi: 10.2500/aap.2011.32.3462.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2500/aap.2011.32.3462</ArticleId>
            <ArticleId IdType="pubmed">22195691</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bosma AL, Spuls PI, Garcia-Doval I, et al.  TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema. Br J Dermatol. 2020;182(6):1423–1429. doi: 10.1111/bjd.18452.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjd.18452</ArticleId>
            <ArticleId IdType="pubmed">31444799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bosma AL, de Wijs LE, Hof MH, et al.  Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry. J Am Acad Dermatol. 2020;83(5):1375–1384. doi: 10.1016/j.jaad.2020.05.128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaad.2020.05.128</ArticleId>
            <ArticleId IdType="pubmed">32485210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Plummer M. JAGS: a program for analysis of Bayesian graphical models using Gibbs sampling. Available at : http://mcmc-jags.sourceforge.net/. Updated 14 Sep 2017.</Citation>
        </Reference>
        <Reference>
          <Citation>R Core Team (2020) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/.</Citation>
        </Reference>
        <Reference>
          <Citation>Seo M, Schmid C. Bnma: Bayesian Network Meta-Analysis using 'JAGS'. R package version 1.4.0. https://CRAN.R-project.org/package=bnma.</Citation>
        </Reference>
        <Reference>
          <Citation>Dias S, Welton NJ, Sutton AJ, et al.   NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. Technical support document in evidence synthesis. London: National Institute for Health and Clinical Excellence; 2011. </Citation>
        </Reference>
        <Reference>
          <Citation>Dias SA, Ades AE, Welton NJ, et al.   Statistics in practice. 1. Hoboken: Wiley; 2018. Network meta-analysis for decision-making.</Citation>
        </Reference>
        <Reference>
          <Citation>Silverberg JI, Simpson EL, Thyssen JP, et al.  Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863–873. doi: 10.1001/jamadermatol.2020.1406.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamadermatol.2020.1406</ArticleId>
            <ArticleId IdType="pmc">PMC7271424</ArticleId>
            <ArticleId IdType="pubmed">32492087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simpson EL, Akinlade B, Ardeleanu M. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2017;376(11):1090–1091. doi: 10.1056/NEJMc1700366.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc1700366</ArticleId>
            <ArticleId IdType="pubmed">28296614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simpson EL, Lacour JP, Spelman L, et al.  Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183(2):242–255. doi: 10.1111/bjd.18898.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjd.18898</ArticleId>
            <ArticleId IdType="pubmed">31995838</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simpson EL, Sinclair R, Forman S, et al.  Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255–266. doi: 10.1016/S0140-6736(20)30732-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(20)30732-7</ArticleId>
            <ArticleId IdType="pubmed">32711801</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Simpson EL, Forman S, Silverberg JI, Zirwas M, Maverakis E, Han G, Guttman-Yassky E, Marnell D, Bissonnette R, Waibel J, Nunes FP, DeLozier AM, Angle R, Gamalo M, Holzwarth K, Goldblum O, Zhong J, Janes J, Papp K. Baricitinib in patients with moderate-to-severe atopic dermatitis: results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5) J Am Acad Dermatol. 2021;85(1):62–70. doi: 10.1016/j.jaad.2021.02.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaad.2021.02.028</ArticleId>
            <ArticleId IdType="pubmed">33600915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wollenberg A, Blauvelt A, Guttman-Yassky E, et al.  Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2) Br J Dermatol. 2020;180:437–449.</Citation>
        </Reference>
        <Reference>
          <Citation>Simpson E, Forman S, Silverberg J, et al.  Efficacy and safety of baricitinib in moderate-to-severe atopic dermatitis: results from a randomized, double-blinded, placebo-controlled phase 3 clinical trial (BREEZE-AD5) Br J Dermatol. 2020;183(4):3–4.</Citation>
        </Reference>
        <Reference>
          <Citation>ClinicalTrials.gov. Study to evaluate efficacy and safety of PF-04965842 in subjects aged 12 years and older with moderate to severe atopic dermatitis (JADE Mono-1). Identifier: NCT03349060. https://clinicaltrials.gov/ct2/show/study/NCT03349060. Updated 10 Dec 2019.</Citation>
        </Reference>
        <Reference>
          <Citation>ClinicalTrials.gov. Study to evaluate efficacy and safety of PF-04965842 in subjects aged 12 years and older with moderate to severe atopic dermatitis (JADE Mono-2). Identifier: NCT03575871. https://clinicaltrials.gov/ct2/show/NCT03575871. Updated 21 Apr 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Thaçi D, Simpson EL, Deleuran M, et al.  Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2) J Dermatol Sci. 2019;94:266–275. doi: 10.1016/j.jdermsci.2019.02.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jdermsci.2019.02.002</ArticleId>
            <ArticleId IdType="pubmed">31109652</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med. 2004;23(20):3105–3124. doi: 10.1002/sim.1875.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/sim.1875</ArticleId>
            <ArticleId IdType="pubmed">15449338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Watt J, Tricco AC, Straus S, et al.  Research techniques made simple: network meta-analysis. J Invest Dermatol. 2019;139(1):4–12.e11. doi: 10.1016/j.jid.2018.10.028.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jid.2018.10.028</ArticleId>
            <ArticleId IdType="pubmed">30579427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mills EJ, Thorlund K, Ioannidis JP. Demystifying trial networks and network meta-analysis. BMJ. 2013;14:346.</Citation>
        </Reference>
        <Reference>
          <Citation>Drucker AM, Ellis A, Jabbar-Lopez Z, et al.  Systemic immunomodulatory treatments for atopic dermatitis: protocol for a systematic review with network meta-analysis. BMJ Open. 2018;8(8):e023061. doi: 10.1136/bmjopen-2018-023061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmjopen-2018-023061</ArticleId>
            <ArticleId IdType="pmc">PMC6119412</ArticleId>
            <ArticleId IdType="pubmed">30158235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drucker AM, Ellis AG, Bohdanowicz M, et al.  Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis. JAMA Dermatol. 2020;156(6):659–667. doi: 10.1001/jamadermatol.2020.0796.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamadermatol.2020.0796</ArticleId>
            <ArticleId IdType="pmc">PMC7177646</ArticleId>
            <ArticleId IdType="pubmed">32320001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Siegels D, Heratizadeh A, Abraham S, et al.  Systemic treatments in the management of atopic dermatitis: a systematic review and meta-analysis. Allergy. 2020;76:1053–1076. doi: 10.1111/all.14631.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/all.14631</ArticleId>
            <ArticleId IdType="pubmed">33074565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silverberg JI, Thyssen JP, Fahrbach K, et al.  Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. J Eur Acad Dermatol Venereol. 2021;35:1797–1810. doi: 10.1111/jdv.17351.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jdv.17351</ArticleId>
            <ArticleId IdType="pmc">PMC8453983</ArticleId>
            <ArticleId IdType="pubmed">33991374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thyssen JP, Thomsen SF. Treatment of atopic dermatitis with biologics and Janus kinase inhibitors. Lancet. 2021;397(10290):2126–2128. doi: 10.1016/S0140-6736(21)00717-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(21)00717-0</ArticleId>
            <ArticleId IdType="pubmed">34023007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thyssen J, Vestergaard C, Deleuran M, et al.  European Task Force on Atopic Dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis. J Eur Acad Dermatol Venereol. 2020;34(12):e839–e842. doi: 10.1111/jdv.16716.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/jdv.16716</ArticleId>
            <ArticleId IdType="pubmed">32515512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cipriani A, Higgins JP, Geddes JR, et al.  Conceptual and technical challenges in network meta-analysis. Ann Intern Med. 2013;159(2):130–137. doi: 10.7326/0003-4819-159-2-201307160-00008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/0003-4819-159-2-201307160-00008</ArticleId>
            <ArticleId IdType="pubmed">23856683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salanti G, Del Giovane C, Chaimani A, et al.  Evaluating the quality of evidence from a network meta-analysis. PLoS ONE. 2014;9(7):e99682. doi: 10.1371/journal.pone.0099682.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0099682</ArticleId>
            <ArticleId IdType="pmc">PMC4084629</ArticleId>
            <ArticleId IdType="pubmed">24992266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>A phase 3 randomized, double-blind, placebo-controlled, parallel group, multi-center study to evaluate the efficacy and safety of PF-04965842 monotherapy in subjects aged 12 years and older, with moderate to severe atopic dermatitis. Identifier NCT03575871. In: Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863–873.</Citation>
        </Reference>
        <Reference>
          <Citation>A phase 3 randomized, placebo-controlled, double-blind study to evaluate upadacitinib in adolescent and adult subjects with moderate to severe atopic dermatitis. Identifier NCT03569293. In: Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021 ;397(10290):2151–2168.</Citation>
        </Reference>
        <Reference>
          <Citation>A phase 3 randomized, placebo-controlled, double-blind study to evaluate upadacitinib in adolescent and adult subjects with moderate to severe atopic dermatitis. Identifier NCT03607422. In: Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021 Jun 5;397(10290):2151–2168.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
